Resonance HealthASX:RHT +4.55% Dividend Yield % is 0.00% as of Jun. 24, 2026. The stock has 6 warning signs investors should review. Among 279 Healthcare Providers & Services companies, Resonance Health ranks worse than 358422.58% on this metric.
As of today (2026-06-24), the Trailing Annual Dividend Yield of Resonance Health is 0.00%.
The historical rank and industry rank for Resonance Health's Dividend Yield % or its related term are showing as below:
ASX:RHT's Dividend Yield % is not ranked *
in the Healthcare Providers & Services industry.
Industry Median: 2.41 * Ranked among companies with meaningful Dividend Yield % only.
The growth rate is calculated with least square regression.
For more information regarding to dividend, please check our Dividend Page.
* Please note that "special dividend" is not included in the calculation of dividend per share and related fields.
Resonance Health (ASX:RHT) Dividend Yield % Explanation
Over the long term, the return from dividends has been a significant contributor to the total returns produced by equity securities. Studies by Elroy Dimson, Paul Marsh, and Mike Staunton of Princeton University (2002) found that a market-oriented portfolio, which included reinvested dividends, would have generated nearly 85 times the wealth generated by the same portfolio relying solely on capital gains.
Dividends may also qualify a lower tax rate for investors.
In dividends investing, Payout Ratio and Dividend Growth Rate are the two most important variables for consideration. A lower payout ratio may indicate that the company has more room to increase its dividends.
The historical data trend for Resonance Health's Dividend Yield % can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
ASX:RHT vs VEEV, BTSG, TEM: Dividend Yield % Comparison
For the Health Information Services subindustry, Resonance Health's Dividend Yield %, along with its competitors' market caps and Dividend Yield % data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Resonance Health Dividend Yield % vs Healthcare Providers & Services Industry
For the Healthcare Providers & Services industry and Healthcare sector, Resonance Health's Dividend Yield % distribution charts can be found below:
* The bar in red indicates where Resonance Health's Dividend Yield % falls into.
Resonance Health (ASX:RHT) has a Dividend Yield % of 0.00% as of Jun. 24, 2026. Dividend yield is the ratio of company dividends to the share price. View historical data on Resonance Health and its competitors. According to the industry distribution chart, Resonance Health ranks #999999 out of 279 companies in the Healthcare Providers & Services industry.
Is Resonance Health's Dividend Yield % too high?
Resonance Health's current Dividend Yield % is 0.00%. Based on the distribution chart, Resonance Health ranks #999999 out of 279 companies in the Healthcare Providers & Services industry, which is in the bottom quartile relative to peers.
How does Resonance Health's Dividend Yield % compare to VEEV and BTSG?
According to the Healthcare Providers & Services industry distribution chart, Resonance Health ranks #999999 out of 279 companies for Dividend Yield %. This places Resonance Health in the lower half of its industry. The industry median Dividend Yield % is 2.41. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Dividend Yield % for a Healthcare Providers & Services company?
The median Dividend Yield % among Healthcare Providers & Services companies is 2.41, based on 279 companies in the industry. Companies in the top quartile (top 25%) have a Dividend Yield % significantly above this median, while those in the bottom quartile fall well below. However, Dividend Yield % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Dividend Yield % mean?
A high Dividend Yield % can signal that a stock is expensive relative to its fundamentals. Dividend yield is the ratio of company dividends to the share price. View historical data on Resonance Health and its competitors. For the Healthcare Providers & Services industry, the median Dividend Yield % is 2.41 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Resonance Health's current Dividend Yield % is 0.00%. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Resonance Health stock overvalued right now?
Based on GuruFocus' analysis, Resonance Health (ASX:RHT) is currently considered Possible Value Trap. The stock's GF Value™ is A$0.12, compared to a current price of A$0.05 — trading 61.7% below its estimated fair value. The current Dividend Yield % is 0.00%. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Dividend Yield % calculated?
Dividend Yield % is calculated from a company's financial statements. For Resonance Health (ASX:RHT), the current Dividend Yield % is 0.00% as of Jun. 24, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Resonance Health Ltd is engaged in the development and commercialisation of software-as-medical-device (SaMD) technologies and services for the quantitative analysis of radiological images in a regulated and quality-controlled environment. The Group's core SaMD product is FerriScan, a non-invasive liver analysis technology used for the assessment of iron in the liver. The Company also has several AI-assisted SaMDs including FerriSmart, HepaFatSmart, and LiverSmart. Its business segments are; SaMD1 which derives key revenue, Corporate, TrialsWest, and Resonance Clinica. Geographically, it generates maximum revenue from the Asia Pacific region and the rest from North America, and Europe, Middle East and Africa (EMEA) regions.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
ASX:RHT has been successfully added to your 